BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24995708)

  • 1. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.
    Matveev SV; Spielmann HP; Metts BM; Chen J; Onono F; Zhu H; Scheff SW; Walker LC; LeVine H
    J Neurochem; 2014 Nov; 131(3):356-68. PubMed ID: 24995708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
    J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.
    Rosen RF; Ciliax BJ; Wingo TS; Gearing M; Dooyema J; Lah JJ; Ghiso JA; LeVine H; Walker LC
    Acta Neuropathol; 2010 Feb; 119(2):221-33. PubMed ID: 19690877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.
    Diner I; Dooyema J; Gearing M; Walker LC; Seyfried NT
    Bioconjug Chem; 2017 Oct; 28(10):2627-2637. PubMed ID: 28862836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.
    Beckett TL; Webb RL; Niedowicz DM; Holler CJ; Matveev S; Baig I; LeVine H; Keller JN; Murphy MP
    J Alzheimers Dis; 2012; 32(1):127-38. PubMed ID: 22766739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
    Ni R; Gillberg PG; Bergfors A; Marutle A; Nordberg A
    Brain; 2013 Jul; 136(Pt 7):2217-27. PubMed ID: 23757761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.
    Fodero-Tavoletti MT; Smith DP; McLean CA; Adlard PA; Barnham KJ; Foster LE; Leone L; Perez K; Cortés M; Culvenor JG; Li QX; Laughton KM; Rowe CC; Masters CL; Cappai R; Villemagne VL
    J Neurosci; 2007 Sep; 27(39):10365-71. PubMed ID: 17898208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.
    Rosen RF; Walker LC; Levine H
    Neurobiol Aging; 2011 Feb; 32(2):223-34. PubMed ID: 19329226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Structural Modifications on the Competition of Chalcones for the PIB Amyloid Imaging Ligand-Binding Site in Alzheimer's Disease Brain and Synthetic Aβ Fibrils.
    Fosso MY; McCarty K; Head E; Garneau-Tsodikova S; LeVine H
    ACS Chem Neurosci; 2016 Feb; 7(2):171-6. PubMed ID: 26682772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan.
    LeVine H; Spielmann HP; Matveev S; Cauvi FM; Murphy MP; Beckett TL; McCarty K; Lott IT; Doran E; Schmitt F; Head E
    Neurobiol Aging; 2017 Jun; 54():163-169. PubMed ID: 28385551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
    Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
    J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anionic Oligothiophenes Compete for Binding of X-34 but not PIB to Recombinant Aβ Amyloid Fibrils and Alzheimer's Disease Brain-Derived Aβ.
    Bäck M; Appelqvist H; LeVine H; Nilsson KP
    Chemistry; 2016 Dec; 22(51):18335-18338. PubMed ID: 27767229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology.
    Hatsuta H; Takao M; Ishii K; Ishiwata K; Saito Y; Kanemaru K; Arai T; Suhara T; Shimada H; Shinotoh H; Tamaoka A; Murayama S
    Curr Alzheimer Res; 2015; 12(3):278-86. PubMed ID: 25731622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.